GeneNews to Present Liver Cancer Data at ASCO 2012
TORONTO, CANADA (April 16, 2012):
"The applications of our proprietary Sentinel Principle® platform continue to expand and demonstrates the utility of this blood-based technology to enable early disease detection and improve disease management. We look forward to presenting our work in the field of liver cancer at this year's ASCO meeting," said Gailina J. Liew, President and Chief Operating Officer of GeneNews.
GeneNews is an emerging molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management based on disease-specific biomarkers. The Company has a patented core platform technology, the Sentinel Principle®, which has the power to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle® in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. The Company's lead product, ColonSentry™, is a convenient, patient-friendly blood-based test that can be incorporated into a routine physical exam to assess an individual's current risk of having colorectal cancer. For more information on GeneNews and ColonSentry™, visit www.genenews.com and www.colonsentry.com.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.